RMD
vs
S
S&P/ASX 300
RMD
Over the past 12 months, RMD has underperformed S&P/ASX 300, delivering a return of -6% compared to the S&P/ASX 300's +16% growth.
Stocks Performance
RMD vs S&P/ASX 300
Performance Gap
RMD vs S&P/ASX 300
Performance By Year
RMD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Resmed Inc
Glance View
ResMed Inc. has built its legacy on a profound, technological commitment to improving the lives of millions worldwide who suffer from sleep-related breathing disorders. Emerging as a beacon in the field of medical device innovation, the company is renowned for its focus on designing and manufacturing equipment to treat sleep apnea, a condition where breathing repeatedly stops and starts during sleep. Their product line, which includes continuous positive airway pressure (CPAP) devices, ventilators, and masks, caters to hospitals, home healthcare settings, and individuals. By addressing this critical health issue, ResMed doesn't just deliver therapeutic equipment; it offers a lifeline to those battling sleep health challenges, ensuring that restful nights translate into healthier days. The company's revenue model pivots around an integrated approach combining hardware sales, software solutions, and cloud-connected offerings. Through its software, ResMed analyzes vast pools of patient data, enabling healthcare providers to tailor and improve therapeutic protocols, thus driving the efficacy of treatment plans. The increasing turn towards digital health technologies has also opened new avenues, with the company's cloud platforms and analytics delivering value-added insights to care providers. This convergence of medical equipment and digital technology provides ResMed not just a steady growth trajectory, but also positions it at the forefront of a healthcare evolution, turning data-driven intelligence into actionable health solutions.
